Home Biotechnology Novartis AG
N

Novartis AG

Profile managed by Bizz Id
Switzerland 500+ employees

Description

Novartis is a medicines company developing treatments in cardiovascular, renal and metabolic disease, immunology, neuroscience and oncology. It works with biotherapeutics, RNA therapies, radioligand therapy and gene and cell therapy platforms. Its products are sold in 118 countries.

Products

19 products
Abelacimab

FXI inhibitor. Atrial fibrillation (stroke prevention). Phase 3 (planned filing 2028).

Under development

Finished product (FDF)

Verified on 2026-10-21

Abelacimab: see suppliers →

Aldesleukin

Brand: Proleukin. Oncology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aldesleukin: see suppliers →

Basiliximab

Brand: Simulect. For injection.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Basiliximab: see suppliers →

Brolucizumab

Brand: Beovu. Intravitreal injection.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Brolucizumab: see suppliers →

Canakinumab

Brand: Ilaris. Immunology and dermatology; subcutaneous injection.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Canakinumab: see suppliers →

Crizanlizumab

Brand: Adakveo. P-selectin inhibitor; intravenous injection. Sickle cell disease, pediatrics in Phase 3.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Crizanlizumab: see suppliers →

Erenumab

Brand: Aimovig. CGRP receptor antagonist; subcutaneous injection. Migraine, pediatrics in Phase 3.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Erenumab: see suppliers →

GIA632 (anti-IL-15)

IL-15 mAb. Atopic dermatitis and vitiligo. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ianalumab

VAY736. BAFF-R inhibitor, ADCC-mediated B-cell depletor. Sjögren's disease in registration; lupus nephritis, SLE, immune thrombocytopenia and warm autoimmune hemolytic anemia in Phase 3; systemic sclerosis in Phase 2.

Solicitud presentada (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ianalumab: see suppliers →

Interferon beta-1b

Brand: Extavia.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Lifonebart

VHB937. TREM2 stabilizer and activator. Alzheimer's disease and amyotrophic lateral sclerosis. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Lifonebart: see suppliers →

Ofatumumab (ref. Arzerra)

Brand: Arzerra.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ofatumumab: see suppliers →

Ofatumumab (ref. Kesimpta)

Brand: Kesimpta. CD20 antagonist; subcutaneous injection; neuroscience. Multiple sclerosis (new dosing regimen, pediatrics) in Phase 3.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ofatumumab: see suppliers →

Omalizumab

Brand: Xolair. Immunology and dermatology; subcutaneous injection.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Omalizumab: see suppliers →

Pacibekitug

PAC001. Anti-IL-6 mAb. Atherosclerotic cardiovascular disease and thyroid eye disease. Phase 2.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pacibekitug: see suppliers →

PIT565 (anti-CD19/CD2/CD3)

Anti-CD19, anti-CD2, anti-CD3. Rheumatoid arthritis and systemic lupus erythematosus. Phase 1.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab

Brand: Lucentis. Ophthalmology.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

Secukinumab

Brand: Cosentyx. IL-17A inhibitor; subcutaneous injection. Polymyalgia rheumatica in registration.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Secukinumab: see suppliers →

Zigakibart

Anti-APRIL monoclonal antibody. IgA nephropathy. Phase 3 (planned filing 2027).

Under development

Finished product (FDF)

Verified on 2026-10-21

Zigakibart: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free